A mechanistically promising compound can have opposing effects across behavioral domains.
What the paper found
In an immune-mediated mouse neurodevelopmental model, SH-053-2F-S-CH3 reduced an amphetamine-hypersensitivity phenotype. It did not normalize working memory or social interaction; performance in those domains worsened in treated animals.
What the evidence cannot establish
This was an experimental positive allosteric modulator and a mouse model, not a clinical trial of ordinary benzodiazepines in schizophrenia or autism. Receptor selectivity does not establish broad cognitive benefit.
Implications for forensic review
Report both favorable and unfavorable endpoints. A single improved behavior cannot support a claim that the compound corrected the whole disorder. For expert interpretation, specify the tested phenotype and avoid extrapolating experimental receptor pharmacology to an individual’s functioning.
Source and related reading
Source: PMC4360215, supplied full-text paper. Findings are paraphrased; case-review implications are an interpretation.
Related: An Experimental 2,3-Benzodiazepine’s Mouse Profile Does Not Establish Human Freedom From Sedation.
Leave a Reply